Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia

Brazilian Journal of Medical and Biological Research

G.a.p. Oliveira²  E.s. Costa¹  M.s. Freitas¹  F.f. Dutra²  S.f. Maia¹  M.c. Guerra¹  M.d. Tabernero¹  R. Borojevic²  I.b. Otazu²  J.l. Silva¹ 

[1] ,Universidade Federal do Rio de Janeiro Instituto de Ciências Biomédicas Hospital Universitário Clementino Fraga Filho and Departamento de Histologia e EmbriologiaRio de Janeiro RJ ,Brasil

关键词: Chronic myeloid leukemia;    Imatinib mesylate;    Minimal residual disease;    Children;   

DOI  :  10.1590/S0100-879X2010007500026

来源: SciELO

【 摘 要 】

Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License